The humoral immune system has a key prognostic impact in node-negative breast cancer

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5405-5413

  Schmidt, Marcus ^a   Böhm, Daniel ^a   Von Törne, Christian ^b   Steiner, Eric ^a   Puhl, Alexander ^a   Pilch, Henryk ^c   Lehr, Hans Anton ^d   Hengstler, Jan G ^c   Kölbl, Heinz ^a   Gehrmann, Mathias ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID RECEPTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BIOLOGY; BREAST CARCINOMA; CALCULATION; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELL PROLIFERATION; CLUSTER ANALYSIS; COHORT ANALYSIS; GENE; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNE SYSTEM; INFORMATION; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; T LYMPHOCYTE; VALIDATION STUDY; ANTIBODY PRODUCTION; BREAST TUMOR; CARCINOMA; CLINICAL TRIAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEUTROPHIL INFILTRATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 44849101184     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5206     Document Type: Article

References (34)

1. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
2. Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 1981;48:974-9.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406: 747-52.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
5. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11: 5678-85.
6. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
7. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
8. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
9. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-71.
10. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
11. Sotiriou C, Wirapati P, Harris A, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
12. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006;24:1656-64.
13. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
14. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14.
15. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
16. Teschendorff AE, Naderi A, Barbosa-Morais NL, et al. A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 2006;7:R101.
17. Teschendorff A, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
18. + breast cancer correlates with lower recurrence rates. Cancer Res 2007;67:10669-76.
19. Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28:859-64.
20. Ridolfi R, Rosen P, Port A, Kinne D, Mike V. Medullary carcinoma of the breast. A clinicopathologic study with 10-year follow up. Cancer 1977;40:1365-85.
21. Alter O, Brown PO, Botstein D. Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A 2000;97: 10101-6.
22. Selaru FM, Yin J, Olaru A, et al. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res 2001;64: 1584-8.
23. Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3:817-9.
24. Di Paola M, Angelici L, Bertolotti A, Colizza S. Host resistance in relation to survival in breast cancer. Br Med J 1974;4:268-70.
25. Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 2006;48:692-701.
26. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-44.
27. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 2001;98:12659-64.
28. Coronella JA, Telleman P, Kingsbury GA, et al. Antigen-driven oligiclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002;169:1829-36.
29. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003;63:3275-80.
30. Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 2002;169:2701-11.
31. Kotlan B, Simsa P, Teillaud JL, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principal concerning the tumor-infiltrating B lymphocytes. J Immunol 2005;175: 2278-85.
32. O'Sullivan C, Lewis CE. Tumor-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994;172: 229-35.
33. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7.
34. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and Th1 cytokine responses by B cells. Int J Cancer 2005;117:574-86.